Lista de obras - Antonio Calles - Dominio Público Uruguay

A Phase 1 Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors

artículo científico publicado en 2018

A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer

artículo científico publicado en 2015

A functional landscape of resistance to ALK inhibition in lung cancer

artículo científico publicado en 2015

A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours

artículo científico publicado en 2018

Aligning Digital CD8(+) Scoring and Targeted Next-Generation Sequencing with PD-L1 Expression: A Pragmatic Approach in Early-Stage Squamous Cell Lung Carcinoma

artículo científico publicado en 2017

Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer.

artículo científico publicado en 2008

Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study

artículo científico publicado en 2014

Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study

artículo científico publicado en 2014

Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior.

artículo científico publicado en 2012

Corrigendum to 'A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours' [Eur J Cancer 104 (November 2018) 1-8]

artículo científico publicado en 2019

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.

artículo científico publicado en 2015

For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity

scientific article published on 27 September 2018

From presentation to paper: Gender disparities in oncological research

artículo científico publicado en 2019

Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.

artículo científico publicado en 2016

Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations

scientific article published on 19 March 2020

Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study

artículo científico publicado en 2018

Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.

artículo científico publicado en 2015

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.

artículo científico publicado en 2015

Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment

artículo científico publicado en 2014

Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors

artículo científico publicado en 2020

Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

artículo científico publicado en 2016

Nephrotic syndrome in a 60-year-old man

scientific article published on 26 May 2020

Observational Prospective Study to Determine the Evolution of the Symptomatic Profile of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients and Its Relation to the Control of the Disease

artículo científico publicado en 2019

Oncology Patient Interest in the Use of New Technologies to Manage Their Disease: Cross-Sectional Survey

scientific article published on 23 October 2018

Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort

artículo científico publicado en 2019

Pharmacogenetics and pharmacogenomics as tools in cancer therapy

artículo científico publicado en 2016

Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors

artículo científico publicado en 2014

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

artículo científico publicado en 2017

Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer

artículo científico publicado en 2014

Primary human non-small cell lung and pancreatic tumorgraft models--utility and applications in drug discovery and tumor biology

artículo científico publicado en 2013

Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer.

artículo científico publicado en 2009

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors

artículo científico publicado en 2017

Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN.

artículo científico publicado en 2010

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.

artículo científico publicado en 2015

The role of immunotherapy in small cell lung cancer

scientific article published on 12 January 2019

Lista de obras de Antonio Calles

A Phase 1 Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors

A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer

A functional landscape of resistance to ALK inhibition in lung cancer

A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours

Aligning Digital CD8(+) Scoring and Targeted Next-Generation Sequencing with PD-L1 Expression: A Pragmatic Approach in Early-Stage Squamous Cell Lung Carcinoma

Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer.

Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study

Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study

Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior.

Corrigendum to 'A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours' [Eur J Cancer 104 (November 2018) 1-8]

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.

For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity

From presentation to paper: Gender disparities in oncological research

Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.

Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations

Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study

Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.

Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment

Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors

Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

Nephrotic syndrome in a 60-year-old man

Observational Prospective Study to Determine the Evolution of the Symptomatic Profile of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients and Its Relation to the Control of the Disease

Oncology Patient Interest in the Use of New Technologies to Manage Their Disease: Cross-Sectional Survey

Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort

Pharmacogenetics and pharmacogenomics as tools in cancer therapy

Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer

Primary human non-small cell lung and pancreatic tumorgraft models--utility and applications in drug discovery and tumor biology

Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer.

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors

Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN.

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.

The role of immunotherapy in small cell lung cancer